Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Erasmus MC Cancer Institute · Centre de Recherche en Cancérologie de Toulouse · +20 more institutions
Abstract
The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The prognosis of patients showing these abnormalities may vary with the choice of therapy. Treatment strategies have shown promise for HR cytogenetic diseases, such as proteasome inhibition in combination with lenalidomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of immunotherapy with lenalidomide or pomalidomide. Careful analysis of cytogenetic subgroups in trials comparing…
Citation impact
- FWCI
- 57.70
- Percentile
- 100%
- References
- 107
Authors
21Topics & keywords
- Lenalidomide
- Pomalidomide
- Multiple myeloma
- Bortezomib
- Oncology
- Carfilzomib
- Internal medicine
- Cytogenetics
Funding
- AAmgen
- CCelgene
- EUEmory University
- CHCarolinas HealthCare System
- NUNational University of Ireland
- SSkylineDx
- UHUniversität Heidelberg
- VUVrije Universiteit Amsterdam
- NANational and Kapodistrian University of Athens
- UDUniversitat de Barcelona
- UDUniversità di Bologna
- NCNagoya City University
- NUNational University Health System
- UOUniversity of Texas MD Anderson Cancer Center